Chlamydia pneumoniae and Mycoplasma pneumoniae

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 6, 2005, Pages 617-624

  Blasi, Francesco ^a   Tarsia, P ^a   Aliberti, S ^a   Cosentini, R ^a   Allegra, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atypical microorganisms; Chlamydia pneumoniae; Community acquired pneumonia; Mycoplasma pneumoniae

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; GEMIFLOXACIN; GLYCOPEPTIDE; HMR 3004; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; LOMEFLOXACIN; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; STREPTOGRAMIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; STANDARD;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; MYCOPLASMA PNEUMONIAE; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA;

EID: 30344484235     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925525     Document Type: Review

References (48)

1. Reimann HA. An acute infection of the respiratory tract with atypical pneumonia. JAMA 1938;111:2377-2384
2. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101:509-515
3. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalisation. Arch Intern Med 1997;157:1709-1718
4. Eaton MD, Meiklejohn G, van Herick W. Studies on the etiology of primary atypical pneumonia: a filtrable agent transmissible to cotton rats, hamster and chick embryos. J Exp Med 1944;79:649-668
5. Chanock RM, Dienes L, Eaton MD. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism (Eaton agent). Science 1963;140:662
6. Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci USA 1962;48:41-49
7. Couch RB. Mycoplasma pneumoniae (primary atypical pneumonia). In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. New York: John Wiley and Sons; 1995:1484
8. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979;214:1666-1672
9. Foy HM, Kenny GE, McMahan R, et al. Mycoplasma pneumoniae pneumonia in an urban area. JAMA 1970;214:1666-1672
10. Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infections in adults. Am J Med 1975;58:229-242
11. Levine DP, Lerner AM. The clinical spectrum of Mycoplasma pneumoniae infections. Med Clin North Am 1978;62:961-978
12. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986;110:34-41
13. Marc E, Le Chaussain M, Moulin F, et al. Reduced lung diffusion capacity after Mycoplasma pneumoniae pneumonia. Pediatr Infect Dis J 2000;19:706-710
14. Tablan OC, Reyes MP. Chronic interstitial pulmonary fibrosis following Mycoplasma pneumoniae pneumonia. Am J Med 1985;79:268-270
15. Koletsky RJ, Weinstein AJ. Fulminant Mycoplasma pneumoniae infection: report of a fatal case and a review of the literature. Am Rev Respir Dis 1980;122:491-496
16. Halal F, Brochu P, Delage G. Severe disseminated lung disease and bronchiectasis probably due to Mycoplasma pneumoniae. Can Med Assoc J 1977;117:1055-1056
17. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986;110:34-41
18. Grayston JT, Kuo CC, Campbell LA, Wang SP. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Sys Bacteriol 1989;39:88-90
19. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999;106:385-390
20. Marrie TJ, Peeling RW, Reid T, De Carolis ED, and the Canadian Community-Acquired Pneumonia Investigators. Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 2003;21:779-784
21. Grayston JT. Chlamydia pneumoniae strain TWAR. Chest 1989;95:664-669
22. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-625
23. Hirai Y, Shiode J, Masayoshi T, Kanemasa Y. Application of an indirect immunofluorescence test for the detection of Mycoplasma pneumoniae in respiratory exudates. J Clin Microbiol 1991;29:2007-2012
24. Kleemola M, Rati R, Karjalainen J, et al. Evaluation of an antigen-capture enzyme immunoassay for rapid diagnosis of Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 1993;12:872-875
25. Madsen RD, Weiner LB, McMillan JA, et al. Direct detection of Mycoplasma pneumoniae antigen in clinical specimens by a monoclonal antibody immunoblot assay. Am J Clin Pathol 1988;89:95-99
26. Kleemola M, Jokinen C. Outbreak of Mycoplasma pneumoniae infection among hospital personnel studied by a nucleic acid hybridisation test. J Hosp Infect 1992;21:213-221
27. Kai M, Kamiya S, Yabe H, et al. Rapid detection of Mycoplasma pneumoniae in clinical samples by the polymerase chain reaction. J Med Microbiol 1993;38:166-170
28. Van Kuppelveld FJ, Johansson KE, Galama JM, et al. 16S rRNA based polymerase chain reaction compared with culture and serological methods for diagnosis of Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 1994;13:401-405
29. Smith TF. Mycoplasma pneumoniae infection: diagnosis based on immunofluorescence titre of IgG and IgM antibodies. Mayo Clin Proc 1986;61:830-831
30. Tompkins LS, Shachter J, Boman J, et al. Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. J Infect Dis 2000;181:S460-S461
31. Boman J, Söderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998;178:274-277
32. Blasi F, Boman J, Esposito G, et al. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis 1999;180:2074-2076
33. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 1995;39:2770-2773
34. Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R. In vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother 1991;35:407-413
35. Hjelm E, Hulten K, Nystrom-Rosander C, Gustafsson I, Engstrand L, Cars O. Assay of antibiotic susceptibility of Chlamydia pneumoniae. Scand J Infect Dis 1997;104(Suppl 104):13-14
36. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, 1-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-1574
37. Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;36:1573-1574
38. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998;42:1515-1516
39. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:682-683
40. Roblin PM, Montalban G, Hammerschlag MR. In vitro activities of OPC-171 16, a new quinolone, ofloxacin and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994;38:1402-1403
41. Kuo C-C, Grayston JT. In vitro drug susceptibility of Chlamydia SP. strain TWAR. Antimicrob Agents Chemother 1988;32:257-258
42. Mills GD, Oehley MR, Arrol B. Effectiveness of β-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456
43. Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996;51:185-189
44. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian community-acquired pneumonia working group. Clin Infect Dis 2000;31:383-421
45. Mandell LA, Bartlett JC, Dowell SF, File TM, Musher DM, Whitney C. Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clin Infect Dis 2003;37:1405-1433
46. Principi N, Esposito S, Blasi F, Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001;32:1281-1289
47. Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002;35:1345-1352
48. Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004;24:171-181